Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tobramycin Nebulization to Prevent MDR-VAP (TOP-MDRVAP)
NCT07856355Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ventilator-associated pneumonia (VAP) comparing Nebulized Tobramycin with Nebulized 0.9% Sodium Chloride Placebo (2 arms). Primary endpoint: 28-Day Cumulative Incidence of Multidrug-Resistant Ventilator-Associated Pneumonia. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tobramycin
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07856355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07856355.